Credit: Celltrion USA. Zymfentra is a subcutaneous formulation of Inflectra, a biosimilar to Remicade. Zymfentra is indicated as maintenance treatment only; all patients must complete an IV induction ...
Please provide your email address to receive an email when new articles are posted on . SEATTLE — Patients with proliferative vitreoretinopathy experienced improved visual acuity after receiving an ...
June 13, 2006 -- The U.S. Food and Drug Administration (FDA) has approved a 2000-IU (5-mL) dose for antihemophilic factor VIII [recombinant] infusion; and an expanded indication for infliximab ...
Please provide your email address to receive an email when new articles are posted on . Use of a second anti-TNF — IV or subcutaneous agent — resulted in early response and long-term remission among ...
The US Food and Drug Administration (FDA) has approved infliximab-dyyb (Zymfentra, Celltrion USA) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn ...
TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results